Kumquat Biosciences Inc. has disclosed son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.

Sitryx Therapeutics Ltd. has identified nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) activators reported to be useful for the treatment of inflammatory disorders.

Blueprint Medicines Corp. has presented epidermal growth factor receptor (EGFR) (mutant) inhibitors reported to be useful for the treatment of cancer.

Abbvie Inc. has described new proteolysis targeting chimera (PROTA) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to tyrosine protein phosphatase nonreceptor type 2 (PTPN2)-targeting moiety reported to be useful for the treatment of cancer, diabetes type 2 and nonalcoholic steatohepatitis.

Reservoir Neuroscience Inc. has disclosed prostaglandin E2 receptor EP2 subtype (PTGER2; EP2) antagonists reported to be useful for the treatment of inflammation.

Taxis Pharmaceuticals Inc. has synthesized compounds reported to be useful for the treatment of bacterial infections.

Nanchang Helioeast Technology Co. Ltd. has patented oxa-spirocyclic compounds acting as lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors and reported to be useful for the treatment of acute myeloid leukemia.

Medshine Discovery Inc. has synthesized nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, inflammatory bowel disease and systemic lupus erythematosus.

Hangzhou Innogate Pharma Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer and viral infections.

Coherent Biopharma Ltd. has divulged peptide-drug conjugates comprising cytotoxic drug covalently linked to folate receptor α (FOLR1; FR- α)-targeting moiety through linker reported to be useful for the treatment of cancer and metabolic, immunological and neurological disorders.